Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
Janus kinase inhibitors (JAKis) have revolutionized the treatment landscape for various inflammatory and autoimmune diseases since their introduction in 2012. The expanded indications of JAKis have raised concerns about the associated risk of thrombosis, venous thromboembolic events (VTEs), and arte...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037924003625 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|